Biopharmaceutical Archives

Global biopharmaceutical logistics market is expected to grow from US$ 95.66 Bn in 2022 to US$ 171.89 Bn by 2031, at a CAGR of 6.5% during the forecast period 2023-2031.

The global biopharmaceutical logistics market has witnessed significant growth in recent years and is expected to continue growing in the foreseeable future. The demand for bio pharmaceutical logistics services is being driven by several factors, including the increasing demand for personalized medicines, the rising prevalence of chronic diseases, and the growing need for temperature-controlled logistics solutions.

On the supply side, the market is highly competitive, with a large number of players offering a wide range of services. Some of the key players in the market include DHL International GmbH, FedEx Corporation, United Parcel Service, Inc., Deutsche Post AG, and Kuehne + Nagel International AG. These companies are investing heavily in technology and infrastructure to improve their service offerings and gain a competitive edge.

The growth of the biopharmaceutical logistics market is being propelled by several key factors, including the increasing demand for specialized logistics solutions for the transportation of biologics, the growing need for efficient and reliable supply chain management solutions, and the rising adoption of cloud-based logistics solutions. Moreover, the increasing focus on reducing healthcare costs and improving patient outcomes is also driving the growth of the market.

However, the market is not without its challenges. One of the key challenges facing the market is the complex regulatory environment surrounding the transportation of biologics and other pharmaceutical products. Additionally, the high cost of implementing and maintaining temperature-controlled logistics solutions and the increasing competition among players are also major challenges facing the market.

In terms of trends, the biopharmaceutical logistics market is witnessing a shift towards the adoption of blockchain technology to improve supply chain transparency and security. Moreover, the market is also witnessing a growing trend towards the use of drones and autonomous vehicles for the transportation of pharmaceutical products.

Astute Analytica Analysis of the Biopharmaceutical Logistics Market

The global market is characterized by several notable trends and developments. A survey conducted by Pharmaceutical Commerce revealed that 56% of respondents reported that biologics and other temperature-sensitive products comprise more than 50% of their company’s total pharmaceutical sales. This underscores the importance of specialized logistics solutions for the transportation of biopharmaceuticals, which require temperature-controlled environments to maintain their efficacy.

The biopharmaceutical logistics market is highly regulated, with guidelines established by leading organizations such as the International Air Transport Association (IATA), the World Health Organization (WHO), and the U.S. Food and Drug Administration (FDA). These regulations help ensure the safety and quality of pharmaceutical products during transport and storage.

In terms of growth prospects, the Asia Pacific region is expected to witness the highest growth in the biopharmaceutical logistics market. This growth is being driven by factors such as the increasing demand for biologics and biosimilars, as well as rising investments in healthcare infrastructure in countries such as China and India.

The use of blockchain technology in biopharmaceutical logistics is expected to grow significantly in the coming years. Blockchain provides a secure, decentralized platform for managing and tracking pharmaceutical products throughout the supply chain, thereby improving transparency, security, and efficiency.

Another notable trend in the biopharmaceutical logistics industry is the increasing adoption of autonomous vehicles and drones for the transportation of pharmaceutical products. Companies such as UPS and FedEx are already piloting drone delivery services for medical supplies and pharmaceuticals, with the potential to improve the speed and reliability of deliveries while reducing costs.

Challenges and Growth Opportunities in the Biopharmaceutical Logistics Market

Challenges:

Stringent regulatory requirements: The biopharmaceutical logistics market is highly regulated, with strict guidelines set by organizations such as the International Air Transport Association (IATA), the World Health Organization (WHO), and the U.S. Food and Drug Administration (FDA). Compliance with these regulations can be a significant challenge for logistics providers, especially those operating in multiple regions with varying requirements.
Maintaining product integrity: Biopharmaceutical products are highly sensitive and require strict temperature control and monitoring during transport and storage to maintain their efficacy. Any failure to maintain product integrity can result in significant financial losses for manufacturers and distributors.
Supply chain complexity: The biopharmaceutical logistics market supply chain is complex, with multiple stakeholders involved in the transportation and delivery of products. Managing this complexity requires specialized knowledge and expertise, which can be a challenge for logistics providers.
Cost pressures: The high cost of biopharmaceutical products, coupled with the need for specialized logistics solutions, can put significant cost pressures on manufacturers and distributors.

Growth opportunities:

Technological advancements: The adoption of new technologies such as blockchain, IoT, and AI is expected to provide significant growth opportunities for the biopharmaceutical logistics market. These technologies can help improve transparency, security, and efficiency throughout the supply chain.
Emerging markets: The increasing demand for biopharmaceutical products in emerging markets such as Asia Pacific and Latin America is expected to drive significant growth in the biopharmaceutical logistics market. Logistics providers that are able to establish a strong presence in these markets will be well-positioned to capitalize on this growth opportunity.
Specialized solutions: The growing complexity of the biopharmaceutical supply chain is creating a need for specialized logistics solutions, including temperature-controlled transportation and storage, cold chain management, and specialized packaging. Logistics providers that are able to offer these solutions will be well-positioned to capture market share.
Partnership and collaboration: Collaboration and partnership between logistics providers, pharmaceutical manufacturers, and distributors can help create more efficient and effective supply chain solutions. This can help drive growth and innovation in the biopharmaceutical logistics market.

Cold Chain to Generate More than US$ 112.25 Billion Revenue of Global Biopharmaceutical by 2031

The global cold chain market is crucial for the safe transportation and storage of temperature-sensitive products such as pharmaceuticals, vaccines, and perishable foods. The market is expected to grow at a CAGR of 7.2%, generating more than US$ 112.25 billion in revenue by 2031. The increasing demand for temperature-controlled transportation and storage solutions, particularly in emerging economies, is driving this growth.

E-commerce has also contributed to the trend in the global biopharmaceutical logistics market, as consumers expect fresh and high-quality products delivered to their doorstep. The COVID-19 pandemic has highlighted the importance of the cold chain industry in the distribution of vaccines and other medical supplies. However, challenges such as the high cost of maintaining temperature-controlled infrastructure and equipment, and inconsistent regulatory oversight in developing economies pose significant obstacles to industry growth. Despite these challenges, the growth potential of the cold chain market remains strong, particularly with ongoing investments in technology and personnel to address these challenges.

Air Shipping of the Biopharmaceuticals to bring in a Revenue of Over US$ 68.26 Billion by 2031

The global biopharmaceutical logistics market is experiencing significant growth due to the rise of innovative and effective therapies to treat various diseases. The transportation of these products has become increasingly important, and air shipping has become a crucial mode of transportation for the biopharmaceutical industry. Air shipping is preferred because it is fast, efficient, and reliable, allowing for faster delivery times which is particularly important for vaccines that need to be transported quickly to prevent spoilage.

The COVID-19 pandemic has further highlighted the importance of air shipping for biopharmaceuticals, ensuring that these products reach their intended destinations on time. The projected revenue of over US$ 68.26 billion by 2031 for air shipping of biopharmaceuticals reflects the growing demand for this mode of transportation. Advances in technology and logistics are expected to make air shipping even more efficient and reliable in the coming years across global biopharmaceutical logistics market, further boosting demand. Challenges that need to be addressed include ensuring product safety during transportation and regulatory compliance issues. Air shipping is poised to become a significant revenue generator for the biopharmaceutical industry as the demand for biopharmaceuticals increases and the need for faster delivery times continues to grow.

Some of the Top Market Players Are:

Deutsche Post DHL
Kuehne+Nagel
DB Schenker
FedEx
AmerisourceBergen
XPO Logistics
Panalpina
Versacold
Agility
DSV
UPS
Other Prominent Players

In recent years, we have seen Pharmaceutical company megadeals that saw Takeda acquiring Shire for a total value of $81.7 billion, Bristol-Myers Squibb’s acquisition of Celgene for $74 billion, AbbVie’s $63 billion acquisition of Allergan and the proposed acquisition of Alexion by AstraZeneca for $39 billion. All of these acquisitions continue to have a lasting impact on the leadership and staff at these companies which collectively employ hundreds of thousands of employees worldwide. In addition, there have been a plethora of product transfers between organizations with larger multi-national companies pruning portfolios, adding gene therapy and biotechnology divisions, and consolidating core assets.

Mergers and acquisitions (M&As) in the Pharmaceutical/Biopharmaceutical industry are critical for organizations to implement strategic changes to their business. Whether it be to (a) future proof an organization’s pipeline by accessing innovation, (b) obtain additional manufacturing capacity or (c) to divest non-core assets (products, facilities, etc.), companies continue to grow, modernize and evolve to meet the targets set out in their strategic plans.

When two or more organizations reach the ‘deal’ and it is announced that ‘A’ will take over ‘B’ or that A and B will share in ‘A-B’, or indeed that ‘A’ will sell part of their organization to ‘B’, it is frequently followed by uncertainty and apprehension among internal stakeholders. This changing landscape tests an organization’s ability to communicate the distinct ‘win-win’ elements of the deal. The Kübler-Ross change curve (see fig.1 below) is always worth having in mind during this transitional period of M&A and never fails in tracking the internal stakeholder mindset, albeit with differing levels of severity.

Figure 1. Kübler-Ross Change Curve

The transition from pre-M&A to the post-M&A reality can be both fast and slow. The physical symbols of such transitions such as the company name, logo, and headed paper can be changed in a matter of minutes but the hearts and minds of management and employees can lag significantly further behind. It can take years before a post-M&A steady state is reached (sometimes never!) where full commitment to the change is obtained and all the anticipated ‘win-wins’ are realized.

Some acquired organizations are left to their own devices (pardon the pun medtech sector!) and they are run as true satellites whose contact with the corporate office is limited to communicating the positive financial results. In this scenario, the management team in-situ at the time of the M&A event are trusted to continue as-is and maintain the upward trajectory. Alternatively, and more commonly where there is a dominant merging partner, a strict cut-over timeline is applied for an acquired entity to morph into a fully incorporated affiliate. Typically, these sites implement corporate structures, policies and systems swiftly and assertively.

Where M&A becomes can be interesting is the cultural piece; everyone who has worked in an organization through a merger or acquisition knows that there can be a seismic shift in the objectives of the new organization… not so much what the objectives are but, how the objectives are expected to be met. Post M&A, organizations frequently change structure with new reporting lines, new titles, merged departments, increased/reduced layers of management with revised spans of control. Systems of work can also change where new policies are cascaded into procedures that are followed with varying degrees of success. Supporting systems, software tools and information flows are further material changes that tend to require extensive training and oversight in the early periods post-M&A.

When cultures collide in merging organizations, it has serious ramifications for business and its stakeholders. The industry is littered with mergers and takeovers that did not meet expectations simply because the cultural differences were too difficult to overcome. Naturally, organizations do not admit to failed mergers or acquisitions too often but some of the more interesting ones are referenced below.¹ Very often the differences in personal and collective discipline, personified in the leadership differences in the two organizations, is challenging for the organizations to reconcile. Where rigid, structured and conservative management methods meet innovative and unorthodox management can be a recipe for M&A difficulties.²

At PharmaLex, we believe we have a unique understanding of the cultural challenges experienced during Mergers and Acquisitions. Having merged ourselves in 2017 into PharmaLex, we have insight in how to overcome the challenges of maintaining agility while benefitting from working in a bigger corporate environment, having economies of scale with an increased resource pool. In addition, we have supported numerous Quality and Regulatory functions through these challenging periods through Gap Assessments, Benchmarking Studies, Cultural Assessments, Staff Augmentation, Organisational Optimisation and Leadership Coaching and Mentoring. If you would like our team to assist you or your organization with some of the challenges of changing culture, please connect with us to discuss on +353 1 846 4742 or contact@pharmalex.com

__________________________________________________________________

References

https://www.fiercepharma.com/special-report/top-15-m-a-mistakes

https://hbr.org/2018/10/one-reason-mergers-fail-the-two-cultures-arent-compatible

Global Biopharmaceutical Logistics Market to Surpass Valuation of US$ 171.89 billion by 2031

most viewed today